Oral phosphate binders in CKD - is calcium the (only) answer?

Area of Science:

• Nephrology
• Cardiology
• Clinical Pharmacology

Background:

• Abnormal serum phosphate levels in chronic kidney disease (CKD) are linked to increased all-cause and cardiovascular mortality.
• Elevated phosphate is associated with adverse cardiac and renal outcomes in CKD patients.
• Managing serum phosphate is critical for preventing complications related to calcium and parathyroid hormone (PTH) dysregulation.

Purpose of the Study:

• To review the current understanding of serum phosphate management in CKD.
• To discuss the efficacy and safety profiles of various phosphate binders.
• To highlight the importance of early intervention strategies for hyperphosphatemia in CKD.

Main Methods:

• Literature review of studies on phosphate binders in CKD patients.
• Analysis of evidence regarding the effectiveness of different phosphate binders.
• Discussion of safety concerns and long-term toxicities associated with phosphate binder therapy.

Main Results:

• Most phosphate binders demonstrate comparable efficacy to placebo in reducing serum phosphate in adults.
• Sevelamer hydrochloride may offer a slight efficacy advantage over calcium acetate or lanthanum carbonate.
• Calcium-based phosphate binders are frequently prescribed due to cost-effectiveness.

Conclusions:

• Early initiation of phosphate binders alongside dietary modifications is a key strategy for managing hyperphosphatemia in CKD.
• Achieving normal serum phosphate levels in dialysis patients often requires adjunctive dialytic therapies.
• The long-term safety profiles and potential toxicities of phosphate binders necessitate careful consideration.